Abstract: The present disclosure relates to a tingling composition and the use thereof to provide trigeminal sensory stimulation at a dosage and a viscosity effective to improve the swallowing function of patients suffering from dysphagia. The present disclosure provides people suffering from dysphagia with a novel type of solution combining a thickening agent, a tingling composition, and optionally a trigeminal ingredient at the right concentrations. The present disclosure discloses, a tingling composition, specifically, an effervescent composition or an easy and/or fast dissolving thickener composition formulated for dilution into a nutritional product, a nutritional product made from the composition, a ready-to-drink (RTD) beverage, a use of the composition, a method for making a nutritional product from the composition, and a related system.

Abstract: Compositions contain an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to promote a swallowing reflex. The composition containing the combination of cinnamaldehyde and zinc can be used in a method to treat dysphagia and/or prevent aspiration pneumonia from dysphagia. In an embodiment, the composition containing cinnamaldehyde is administered to a human. The composition containing cinnamaldehyde may be a medicament, a food product or a supplement to a food product.

Abstract: The invention pertains to a composition containing a combination of cinnamaldehyde and zinc. The composition containing the combination of cinnamaldehyde and zinc can be used in a method to support weight management or promote weight loss, a method for preventing obesity or overweight, and a method for treating obesity or overweight. In an embodiment, the composition containing the combination of cinnamaldehyde and zinc is administered to a human. The composition may be a medicament, a food product or a supplement.

Abstract: Compositions for treatment or prevention of autism disorders are provided, and the compositions contain a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combinations thereof. Methods for treatment or prevention of autism disorders are also provided, and the methods include administering such compositions.

Abstract: Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The cinnamaldehyde is supplemented by zinc, and the combination can be effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation. The composition comprising the combination of cinnamaldehyde and zinc can be used in a method to support weight management or promote weight loss, a method for preventing obesity or overweight, and a method for treating obesity or overweight. The composition can improve one or more of insulin sensitivity, glucose tolerance, cognitive performance, cognition, mood or memory.

Abstract: Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The cinnamaldehyde is supplemented by zinc, and the combination can be effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation. The composition comprising the combination of cinnamaldehyde and zinc can be used in a method to support weight management or promote weight loss, a method for preventing obesity or overweight, and a method for treating obesity or overweight. The composition can improve one or more of insulin sensitivity, glucose tolerance, cognitive performance, cognition, mood or memory.

Abstract: Compositions can comprise the catechin metabolite 3?-O-methyl-4?-O-sulfate epicatechin. In some embodiments, the composition can be used in a method for blood vessel dilation and/or increased delivery of blood flow to tissues in the body, for example by administering the composition to an individual having or at risk of high blood pressure or a cardiovascular disease. In some embodiments, the compositions are used for weight maintenance or weight loss. In further embodiments the compositions are used for treating or preventing gestational diabetes mellitus. The compositions may be administered orally as a food product in which the 3?-O-methyl-4?-O-sulfate epicatechinis present in a concentration of at least 0.01 mg/g of the food product.

Abstract: Compositions can comprise the catechin metabolite 3?-O-methyl-5-O-sulfate epicatechin. In some embodiments, the composition can be used in a method for blood vessel dilation and/or increased delivery of blood flow to tissues in the body, for example by administering the composition to an individual having or at risk of high blood pressure or a cardiovascular disease. In some embodiments, the compositions are used for weight maintenance or weight loss. In further embodiments the compositions are used for treating or preventing gestational diabetes mellitus. The compositions are preferably administered orally as a food product in which the 3?-O-methyl-5-O-sulfateepicatechinis present in a concentration of at least 0.01 mg/g of the food product.

Abstract: Compositions can comprise the flavanol metabolite 3?-O-glucuronide epicatechin (3GEC). In some embodiments, the amount of 3GEC is effective to increase energy expenditure, sympathetic nervous system activity, and/or fat oxidation. Such a composition can be used in a method to support weight management or promote weight loss, a method for preventing obesity or overweight, and a method for treating obesity or overweight. In some embodiments, the composition can improve insulin sensitivity, glucose tolerance, cognitive performance, cognition, mood and/or memory. In some embodiments, the composition can achieve a therapeutic effect selected from the group consisting of blood vessel dilation, reduced blood pressure, increased delivery of blood flow to tissues in the body, improvement of blood circulation, e.g. in brain, stimulation of protein synthesis, increased release of growth factors, enhanced immune function, and combinations thereof. In some embodiments, the composition can treat or prevent dysphagia, e.g.

Abstract: Compositions for treatment or prevention of autism disorders are provided, and the compositions contain a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combinations thereof. Methods for treatment or prevention of autism disorders are also provided, and the methods include administering such compositions.

Abstract: Compositions for treatment or prevention of autism disorders are provided, and the compositions contain a therapeutically effective amount of a compound selected from the group consisting of Menthol, Linalool, Icilin and combinations thereof. Methods for treatment or prevention of autism disorders are also provided, and the methods include administering such compositions.

Abstract: Compositions contain an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to promote a swallowing reflex. The composition containing the combination of cinnamaldehyde and zinc can be used in a method to treat dysphagia and/or prevent aspiration pneumonia from dysphagia. In an embodiment, the composition containing cinnamaldehyde is administered to a human. The composition containing cinnamaldehyde may be a medicament, a food product or a supplement to a food product.

Abstract: Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to promote a swallowing reflex. The composition comprising the combination of cinnamaldehyde and zinc can be used in a method to treat dysphagia and/or prevent aspiration pneumonia from dysphagia. In an embodiment, the composition comprising cinnamaldehyde is administered to a human. The composition comprising cinnamaldehyde may be a medicament, a food product or a supplement to a food product.

Abstract: Compositions can comprise the flavanol metabolite 4?-O-glucuronide epicatechin (4GEC). In some embodiments, the composition can be used in a method for blood vessel dilation and/or increased delivery of blood flow to tissues in the body, for example by administering the composition to an individual having or at risk of high blood pressure or a cardiovascular disease. In some embodiments, the compositions are used for weight maintenance or weight loss. The compositions are preferably administered orally as a food product in which the 4?-Oglucuronide is present in a concentration of at least 0.01 mg/g of the food product.

Abstract: Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation, relative to a composition lacking cinnamaldehyde but otherwise identical. The composition comprising cinnamaldehyde can be used in a method to support weight management or promote weight loss, a method for preventing obesity or overweight, and a method for treating obesity or overweight. In an embodiment, the composition comprising cinnamaldehyde is administered to a human. The composition comprising cinnamaldehyde may be a medicament, a food product or a supplement to a food product.

Abstract: Compositions contain a therapeutically effective amount of p-anisaldehyde for at least one of provoking the swallowing reflex of dysphagic patients, decreasing appetite by delaying gastric emptying, reducing body weight gain, or reducing glycemia by improving insulin sensitivity, or improving mood, memory or cognition. Methods are provided that include administering such compositions.

Abstract: Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation, relative to a composition lacking cinnamaldehyde and zinc but otherwise identical. The composition comprising the combination of cinnamaldehyde and zinc can be used in a method to support weight managementor promote weight loss, a method for preventing obesity or overweight, and a method for treating obesity or overweight. In an embodiment, the composition comprising cinnamaldehydeis administered to a human. The composition comprising cinnamaldehyde may be a medicament, a food product or a supplement. The composition can improve one or more of insulin sensitivity, glucose tolerance, cognitive performance, cognition, mood or memory.

Abstract: Compositions contain a therapeutically effective amount of p-anisaldehyde for at least one of provoking the swallowing reflex of dysphagic patients, decreasing appetite by delaying gastric emptying, reducing body weight gain, or reducing gylcemia by improving insulin sensitivity, or improving mood, memory or cognition. Methods are provided that include administering such compositions.

Abstract: Compositions contain a therapeutically effective amount of cuminaldehyde for at least one of provoking the swallowing reflex of dysphagic patients, decreasing appetite by delaying gastric emptying, reducing body weight gain, or reducing gylcemia by improving insulin sensitivity or improving mood, memory or cognition. Methods are provided that include administering such compositions.

Abstract: Facial thermography using an infrared camera captures changes of temperature on the face that are induced by modification of the activity of the autonomic nervous system. Changes of the nose temperature are closely correlated with levels of fat oxidation after ingestion of some ingredients. Therefore, methods using facial thermography can measure the impact of a food ingredient on metabolism and more precisely on fat oxidation after consumption.